Arcturus Therapeutics (NASDAQ:ARCT) Cut to Sell at Wall Street Zen

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Saturday.

Several other analysts have also recently issued reports on the company. Scotiabank reissued an "outperform" rating on shares of Arcturus Therapeutics in a research note on Wednesday, July 2nd. BTIG Research set a $48.00 target price on Arcturus Therapeutics and gave the stock a "buy" rating in a research note on Monday, March 10th. Citigroup reissued a "buy" rating on shares of Arcturus Therapeutics in a research note on Tuesday, May 13th. Wells Fargo & Company cut their target price on Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 14th. Finally, Canaccord Genuity Group lowered their price objective on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Arcturus Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $54.00.

Arcturus Therapeutics Price Performance

ARCT traded down $0.42 during trading on Friday, reaching $13.36. The stock had a trading volume of 428,993 shares, compared to its average volume of 421,219. The stock has a market cap of $362.32 million, a PE ratio of -5.28 and a beta of 2.27. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.64 and a current ratio of 5.64. Arcturus Therapeutics has a one year low of $8.04 and a one year high of $25.88. The business has a 50-day moving average of $12.48 and a 200-day moving average of $13.95.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.58) by $1.06. Arcturus Therapeutics had a negative return on equity of 27.41% and a negative net margin of 47.47%. The firm had revenue of $29.38 million for the quarter, compared to analysts' expectations of $25.64 million. As a group, equities research analysts anticipate that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Arcturus Therapeutics

Large investors have recently made changes to their positions in the business. Byrne Asset Management LLC lifted its holdings in shares of Arcturus Therapeutics by 89.8% during the first quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company's stock valued at $31,000 after purchasing an additional 1,365 shares during the last quarter. US Bancorp DE lifted its holdings in shares of Arcturus Therapeutics by 218.9% during the first quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 2,329 shares during the last quarter. Virtus ETF Advisers LLC lifted its holdings in shares of Arcturus Therapeutics by 38.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock valued at $69,000 after purchasing an additional 1,132 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Arcturus Therapeutics during the fourth quarter valued at approximately $71,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Arcturus Therapeutics by 3,482.9% during the first quarter. GAMMA Investing LLC now owns 5,231 shares of the biotechnology company's stock valued at $550,000 after purchasing an additional 5,085 shares during the last quarter. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.